Long non‐coding RNA ADAMTS9‐AS1 inhibits the progression of prostate cancer by modulating the miR‐142‐5p/CCND1 axis

• Published in: The journal of gene medicine 2021-05, Vol.23 (5), p.e3331-n/a
• Main Authors: Zhou, Zhien, Wu, Xingcheng, Zhou, Yi, Yan, Weigang
• Format: Article
• Language: English
• Subjects: ADAMTS9‐AS1; Apoptosis; Apoptosis - genetics; CCND1; Cell growth; Cell Line, Tumor; Cell Movement - genetics; Cell proliferation; Cell Proliferation - genetics; Cyclin D1; Cyclin D1 - genetics; Disease Progression; Gene expression; Gene Expression Regulation, Neoplastic; Gene therapy; Humans; long non‐coding RNA; Male; MicroRNAs - genetics; miRNA; miR‐142‐5p; Non-coding RNA; Polymerase chain reaction; Prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; RNA, Long Noncoding - genetics; Signal Transduction - genetics
• ISSN: 1099-498X; 1521-2254
• DOI: 10.1002/jgm.3331

Background Emerging evidence has implied the importance of long non‐coding RNAs in cancer development, including prostate cancer (PCa). Bioinformatic analyses have identified that ADAMTS9‐AS1 may play a role in cancer progression. Methods A quantitative real‐time polymerase chain reaction was conducted to measure ADAMTS9‐AS1 expression level at messenger RNA level. In vitro functional analyses were performed to investigate cell behaviors status under different conditions. Moreover, rescue assays were conducted to explore the potential mechanisms of ADAMTS9‐AS1 in PCa progression. Results ADAMTS9‐AS1 expression is down‐regulated in PCa. Forcing ADAMTS9‐AS1 expression impedes PCa cell proliferation via initiating cell apoptosis. Importantly, microRNA‐142‐5p (miR‐142‐5p) mimic and small‐interfering RNA targeting cyclin D1 (CCND1, si‐CCND1) could attenuate the inhibitory effects of ADAMTS9‐AS1 overexpression on PCa cell growth. Conclusions Collectively, our results indicate that ADAMTS9‐AS1 suppresses PCa progression by regulating the miR‐142‐5p/CCND1 axis, which provides a new mechanism for the progression of PCa. ADAMTS9‐AS1 serves as a tumor suppressor in prostate cancer by regulating the miR‐142‐5p/CCND1 axis.